These findings suggest that specific IL-23R and ATG-10 genotypes may be associated with differential responses to Sorafenib in patients with advanced HCC, highlighting potential genetic markers for predicting treatment outcomes. The gene discussed is IL23R; the disease is hepatocellular carcinoma.